New diagnosis of stage I-III breast cancer, Yes Yes surgery at BWH, chemotherapy at DFCI New diagnosis of stage I-III breast cancer, Yes No surgery at MGH, chemotherapy at MGH New diagnosis of stage I-III breast cancer, Yes No surgery at outside hospital, chemotherapy at DFCI New diagnosis of stage I-III breast cancer, No No second opinion only, not treated at DFCI or MGH New diagnosis of stage I-III breast cancer, Yes Yes surgery at Faulkner Hospital, chemotherapy at DFCI New diagnosis of stage I-III breast cancer, No Yes surgery at Faulkner Hospital, no treatment at DFCI or BWH main campus New diagnosis of de novo metastatic breast Yes Yes cancer, treated at DFCI New diagnosis of recurrent metastatic breast No No cancer, previous treatment for stage II breast cancer at outside hospital Presenting for second opinion for second line No No therapy for metastatic breast cancer, consult only Presenting for second opinion for second line No No therapy for metastatic breast cancer (treated elsewhere prior), and subsequently transfers care to DFCI 11-104: Profile - Research on Clinically Acquired Patient Material in Cancer Principal Investigator – Bruce Johnson, MD Overall Accrual: 594 - Oncomap testing, 1,130 - Oncopanel testing Accrual of patients with primary diagnosis of breast cancer: XX 11-104 (Profile) is the umbrella protocol for clinical data, tissue collection and genomic testing of tumors across DFCI, BWH, and Boston’s Children’s Hospital. Patients have been consented since 2011. There have been different versions of the assay used since 2011. The Oncomap assay was used from 8/01/2011 through the end of September 2013 from DFCI (adult and pediatric), BWH (Adults) and consult patients referred from other hospitals to DFCI and BWH are included. Three versions of OncoPanel tests are included in the database:OncoPanel Version 1 (v1) data includes patients sequenced between 6/26/2013 and 8/6/2014. Oncopanel
New diagnosis of stage I-III breast cancer, surgery at BWH, chemotherapy at DFCI Yes Yes New diagnosis of stage I-III breast cancer, surgery at MGH, chemotherapy at MGH Yes No New diagnosis of stage I-III breast cancer, surgery at outside hospital, chemotherapy at DFCI Yes No New diagnosis of stage I-III breast cancer, second opinion only, not treated at DFCI or MGH No No New diagnosis of stage I-III breast cancer, surgery at Faulkner Hospital, chemotherapy at DFCI Yes Yes New diagnosis of stage I-III breast cancer, surgery at Faulkner Hospital, no treatment at DFCI or BWH main campus No Yes New diagnosis of de novo metastatic breast cancer, treated at DFCI Yes Yes New diagnosis of recurrent metastatic breast cancer, previous treatment for stage II breast cancer at outside hospital No No Presenting for second opinion for second line therapy for metastatic breast cancer, consult only No No Presenting for second opinion for second line therapy for metastatic breast cancer (treated elsewhere prior), and subsequently transfers care to DFCI No No 11-104: Profile - Research on Clinically Acquired Patient Material in Cancer Principal Investigator – Bruce Johnson, MD Overall Accrual: 594 - Oncomap testing, 1,130 - Oncopanel testing Accrual of patients with primary diagnosis of breast cancer: XX 11-104 (Profile) is the umbrella protocol for clinical data, tissue collection and genomic testing of tumors across DFCI, BWH, and Boston’s Children’s Hospital. Patients have been consented since 2011. There have been different versions of the assay used since 2011. The Oncomap assay was used from 8/01/2011 through the end of September 2013 from DFCI (adult and pediatric), BWH (Adults) and consult patients referred from other hospitals to DFCI and BWH are included. Three versions of OncoPanel tests are included in the database:OncoPanel Version 1 (v1) data includes patients sequenced between 6/26/2013 and 8/6/2014. Oncopanel
FAQ_3-15-2017.docx